铁亡:在心脑血管疾病中是一种潜在的治疗点
Chenlong Jiang1,2, Yang Yan3, Tianlin Long4
1School of Life Sciences, Northwest University, Xi'an, 710069, Shaanxi, China.
Molecular and cellular biochemistry
|March 28, 2025
概括
细胞死亡过程 - - 铁亡是心脑血管疾病 (CCVD) 的关键. 向铁和使用中国草药 (CHM) 显示出新的CCVD治疗的希望.
科学领域:
- 生物医学科学 生物医学科学
- 细胞生物学 细胞生物学
- 心血管研究研究心血管研究
背景情况:
- 心脑血管疾病 (CCVD) 是全球主要的死亡原因,有效治疗方法有限.
- 铁亡是一种受调节的细胞死亡途径,越来越多地被认为是CCVD病变发生的关键因素.
- 了解铁灭的机制对于开发新的治疗策略至关重要.
研究的目的:
- 为了回顾铁灭的核心机制.
- 阐明各种CCVDs中铁亡的病理影响.
- 探索向铁亡的治疗潜力以及中国草药 (CHM) 在CCVD管理中的作用.
主要方法:
- 对铁亡途径的现有文献的审查 (GPX4-GSH-System Xc-, NAD(P) H/FSP1/CoQ10轴).
- 在动脉样硬化,心肌梗塞,缺血-再输液损伤,心肌病和中风中铁化作用的分析.
- 对中国草药中铁灭症缓解特性的研究.
主要成果:
- 铁质受调节的关键途径包括GPX4,GSH,系统Xc,FSP1,CoQ10,脂质过氧化和铁代谢.
- 在各种CCVDs的临床前模型中,抑制铁化表明了治疗潜力.
- 某些中国草药具有可以通过抗氧化和铁化机制减轻铁的特性.
结论:
- 铁亡是CCVD病理学的重要贡献者,提出了一个新的治疗点.
- 向铁亡途径为管理CCVD提供了有希望的途径.
- 中国草药提供一种天然的化合物来源,可以调节铁亡,可能改善CCVD患者的治疗结果.
更多相关视频
06:54A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
Published on: June 22, 2022
3.5K
04:01Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
2.2K
相关概念视频
02:57Targeted Cancer Therapies
9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.2K
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
773
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
773
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
573
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
573
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
619
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
619
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
662
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
662
01:26Atherosclerosis III: Management
603
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603